Twist Bioscience have developed a unique synthesis platform for DNA that radically produces scaled Oligonucleotides. Twist utilise semiconductor technology to manufacture on silicon chips, enabling 1000x more genes to be manufactured then conventional DNA synthesis approaches.
In addition to increasing scale, the Twist manufacturing platform is incredibly efficient in the synthesis approach delivering DNA that is
- Achieves longer strands
- Lower error rate – around 1/2ooo nucleotides
- Faster turnaround time
Clonal Genes and Gene Fragments
Our silicon-based DNA synthesis platform significantly increases gene synthesis throughput and scalability, while reducing turnaround time and price per base. Think bigger, expand your design scope, and accelerate discovery.
We’ve enhanced our Clonal Genes products with additional plasmid prep sizes and other options including normalization, endotoxin-free DNA, and a variety of tube and plate options to meet your research needs.
Twist Oligo Pools are highly diverse collections of single-stranded oligonucleotides synthesized using our silicon-based DNA writing technology. Our synthesis platform enables massively parallel production of hundreds of thousands of high-quality, accurate oligos per run.
Oligo pools are utilized in many applications including generation of CRISPR guide RNA (sgRNA) libraries, peptide screens, protein screens, and high-throughput reporter assays.
Unleash the full power of a well-designed library. With Twist Bioscience, you are assured that the library you design contains the specific modifications, exactly where you want them, saving you valuable resources for the downstream screening process.
Achieve superior enrichment efficiency with Twist Bioscience NGS Target Enrichment Solutions. Targeted sequencing takes a step forward with an optimized enrichment workflow and easy customization of panel content.
Tools for Addressing the SARS-CoV-2 Virus
Twist’s unique silicon-based DNA writing platform allows for the rapid development of NGS panels for viral detection and characterization of samples, and their Clonal Genes and Gene Fragments allow for quick development of subunit vaccines from one or more antigen-presenting viral genes or peptide sequences, which bypasses the need for scientists to handle live and potentially dangerous pathogens, and minimizes the time needed to clone DNA fragments.